ES3025795T3 - Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy - Google Patents

Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy Download PDF

Info

Publication number
ES3025795T3
ES3025795T3 ES19778516T ES19778516T ES3025795T3 ES 3025795 T3 ES3025795 T3 ES 3025795T3 ES 19778516 T ES19778516 T ES 19778516T ES 19778516 T ES19778516 T ES 19778516T ES 3025795 T3 ES3025795 T3 ES 3025795T3
Authority
ES
Spain
Prior art keywords
fgfr3
infigratinib
treatment
bgj398
skeletal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19778516T
Other languages
English (en)
Spanish (es)
Inventor
Laurence Legeai-Mallet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Fondation Imagine
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Fondation Imagine
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Fondation Imagine, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES3025795T3 publication Critical patent/ES3025795T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19778516T 2018-09-28 2019-09-27 Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy Active ES3025795T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306275 2018-09-28
PCT/EP2019/076241 WO2020065034A1 (en) 2018-09-28 2019-09-27 Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy

Publications (1)

Publication Number Publication Date
ES3025795T3 true ES3025795T3 (en) 2025-06-09

Family

ID=63798918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19778516T Active ES3025795T3 (en) 2018-09-28 2019-09-27 Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy

Country Status (5)

Country Link
US (2) US20220040175A1 (https=)
EP (1) EP3856187B1 (https=)
JP (1) JP7390370B2 (https=)
ES (1) ES3025795T3 (https=)
WO (1) WO2020065034A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250198A1 (en) * 2020-06-11 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit
CA3202267A1 (en) * 2020-12-18 2022-06-23 Riccardo Panicucci Methods of treating achondroplasia
EP4452271A1 (en) * 2021-12-20 2024-10-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of a fgfr3 tyrosine kinase inhibitor for the treatment of fgfr-related bone repair and bone formation impairments
JP2026507903A (ja) * 2023-03-06 2026-03-06 キューイーディー セラピューティクス，インコーポレイテッド 骨格形成異常の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133328B2 (en) * 2011-12-12 2015-09-15 Sa Des Eaux Minerales D'evian Saeme Plastic compositions and containers made thereof
WO2013088191A1 (en) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3

Also Published As

Publication number Publication date
EP3856187B1 (en) 2025-03-12
JP7390370B2 (ja) 2023-12-01
WO2020065034A1 (en) 2020-04-02
EP3856187A1 (en) 2021-08-04
US20240285626A1 (en) 2024-08-29
JP2022502408A (ja) 2022-01-11
US20220040175A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
ES3025795T3 (en) Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy
ES2938546T3 (es) Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
JP4123309B2 (ja) 鼻内投与のための薬学的非無機塩類液剤
JP2018528242A (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2010529128A (ja) レット症候群および他の障害の処置
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
RU2592983C2 (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
JP2023159354A (ja) 行動の変化の治療方法
BRPI0613731A2 (pt) composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
JP6959371B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
CN118973603A (zh) 一种glp-1和gip双受体激动剂药物组合物及其用途
EP3468602B1 (en) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
CN114599368A (zh) 四环化合物及其盐、组合物以及其使用方法
Matsushita et al. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia
KR102285724B1 (ko) Dna 단편 혼합물 및 히알루론산을 포함하는 연골 재생용 조성물
TW202247844A (zh) 吡咯并嘧啶類化合物的用途
JP2017514875A (ja) 失禁および他の括約筋不全障害を処置する方法
EP4203956A1 (en) Compositions and uses thereof
EP3737378B1 (en) Palonosetron eye drops for the treatment or prevention of nausea and vomiting
CN113577080B (zh) 一种含杂环的化合物的应用
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
JP2007523827A (ja) 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法
EA002676B1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка